Rosetta Genomics Ltd
OTC:ROSGQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (23.2), the stock would be worth $-57.93 (57 929 200% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0 | $0 |
0%
|
| Industry Average | 23.2 | $-57.93 |
-57 929 200%
|
| Country Average | 19.1 | $-47.76 |
-47 763 175%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IL |
|
Rosetta Genomics Ltd
OTC:ROSGQ
|
593 USD | -0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 29.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 12.9 |
| Median | 19.1 |
| 70th Percentile | 29.8 |
| Max | 1 624.2 |
Other Multiples
Rosetta Genomics Ltd
Glance View
Rosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
